Leave blank for all. Otherwise, the first selected term will be the default instead of "Any".

Letter to Senate Judiciary Committee on Managers Amendment to PATENT Act

BIO submitted a letter to members of the Senate Judiciary Committee regarding the Managers Amendment to PATENT Act.

Key Leaders from Canadian R&D Scientists to Discuss Biomass Sustainability at 2015 BIO World Congress


BIO Thanks USDA for Commitment to Building Renewable Fuel Infrastructure

BIO  thanks Agriculture Secretary Tom Vilsack for making available grants to states that invest in expanding infrastructure for biofuels.

EPA’s Proposed RFS Rules Continue to Undercut Advanced Biofuels, BIO Says

EPA has again proposed rules for the Renewable Fuel Standard that will continue to chill investment in the advanced biofuel sector and increase climate changing emissions.

BIO 2015 to Host an Evening Keynote with Wynton Marsalis

Leading Jazz Musician to share his insights about the correlation between artists and entrepreneurs at the 2015 BIO International Convention

North Carolina Governor McCrory Signs Bill Ensuring Patient Access to Interchangeable Biologic Medicines

BIO & NCBIO commend Governor Pat McCrory for signing critical legislation to create a pathway for the substitution of interchangeable biologic medicines.

BIO Applauds Energy and Commerce Committee for Approving 21st Century Cures Act

Biotechnology Industry Organization praises the Energy and Commerce Committee for approving the 21st Century Cures Act

BIO'S Letter to House Appropriations Agriculture Committee re Section 9003 of the Agricultural Act of 2014

On behalf of the biotechnology industry we are writing to encourage your support of full funding of Section 9003 of the Agricultural Act of 2014 (Public Law 113-79), the Biorefinery, Renewable Chemical, and Biobased Manufacturing Assistance Program, as you develop the Fiscal Year 2016 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act.

BIO Applauds the U.S. House of Representatives for Passage of the American Research and Competitiveness Act

By making this tax credit permanent, companies conducting their development programs will be able to estimate their tax liability and will not be burdened by the constant uncertainty regarding whether or not the R&D Tax Credit will be extended.

BIO Comments on FDA Draft Guidance: Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application

BIO applauds the issuance by the Food and Drug Administration (FDA) of the Draft Guidance entitled, “Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application.” (Draft Guidance)1 The policies and recommendations set forth in the Draft Guidance, when finalized, represent critical steps forward in the effort to protect patients from biological products prepared under conditions that could result in their contamination or a lack of effectiveness.